ERLOTINIB

Erlotinib is a targeted anticancer treatment drug that was approved for its medical use on 18th November 2004

Erlotinib has been developed to treat advanced and metastatic non-small cell lung cancer due to a mutation in the EGFR gene which did not improve after chemotherapy treatment or has worsened after 4 cycles of chemotherapy.

Erlotinib is available in the form of tablets in doses 100mg and 150mg. the usual recommended dose is 150mg per day. Your healthcare provider will calculate the ideal dose according to your condition. Take Erlotinib Tablet with a large glass of water an hour before food or two hours after meals.

The common side effects that are likely to occur while you are on the treatment with Erlotinib are diarrhea, nausea, vomiting, stomach pain, conjunctivitis, tiredness, breathlessness, cough, infection, loss of appetite, rash, pruritus, and dry skin. If you experience any allergic or unusual reactions after taking this medicine, report to your doctor immediately.

It is not recommended to take Erlotinib Tablet if you are allergic to Erlotinib or any of its ingredients. During the Erlotinib treatment, your doctor may periodically monitor your complete blood counts, blood sugar, electrolytes, liver panel, and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with stomach ulcers, cataracts, lung disease, lactose intolerance, or problems in your heart, liver, skin, or kidneys. Tell your physician before you undergo eye surgery or dental procedures.

It is not known if Erlotinib causes harm to an unborn baby. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. It is advised for both men and women to follow proper contraceptive methods during and for 2 weeks after the last dose of Erlotinib. Avoid breastfeeding your baby while you are on the treatment and for 2 weeks after the last dose of Erlotinib.

Use an effective moisturizer to prevent skin dryness. Ensure that you stay hydrated and maintain a balanced diet. Avoid driving or operating heavy machines if you experience dizziness, eye irritation or tiredness while on treatment with Erlotinib. Tell your healthcare provider before taking Erlotinib if you have been diagnosed with lactose intolerance.

1. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Goodman & Gilman’s Pharmacological Basis of Therapeutics, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, 13th Edition, 2018, 1203-1236. 2. Roche, [Revised on Sep 2021] [Accessed on 27th Sep 2022], https://www.rochecanada.com/PMs/Tarceva/Tarceva_PM_E.pdf